AI-generated from publicly available materials.The recent Pharma IT Summit in Mumbai underscored the vital role of ERP transformation in the pharmaceutical industry, focusing on manufacturing continuity and regulatory compliance.
Key insights from industry experts highlighted that modernizing enterprise resource planning (ERP) systems is essential for enhancing agility and ensuring data integrity within life sciences companies. The summit emphasized the importance of adopting artificial intelligence (AI) while maintaining strict adherence to regulatory standards. Notably, the need for human oversight of generative AI outputs was a recurring theme, particularly in environments governed by good practice (GxP) guidelines.
Speakers, including Mandar Ghatnekar from Biocon and Tejomay Pandya from ADVANZ PHARMA, articulated that the successful integration of AI in pharmaceuticals hinges on a robust framework that balances innovation with regulatory compliance. They argued that the effectiveness of AI implementation will ultimately be measured by its ability to deliver sustainable business outcomes rather than merely the number of use cases deployed.
This discourse reflects a pivotal shift in the pharmaceutical sector, where the convergence of technology and regulatory frameworks is becoming increasingly critical. As companies navigate this complex landscape, the emphasis on human review and governance will likely shape the future of AI in the industry, ensuring that technological advancements align with operational excellence and compliance mandates.